HCM IV Acquisition

This is the SPAC's foundational IPO filing. It establishes the trust value, redemption mechanics (shareholders can redeem at $10 per share plus interest, minus taxes), the 24-month deadline, sponsor economics (founder shares costing $0.003 per share vs. public $10.00), and the priority of HCM III over HACQ in deal sourcing. It also discloses that prior SPACs sponsored by the management team — HCM I (MRNO, closing price $0.94) and HCM II (IMSR, $7.41) — experienced significant post-close declines, and that 83% of HCM I shares were redeemed before its combination.

Advancing the registration effective date brings the public offering closer to execution, which operationally precedes the start of the business combination search period and the initiation of any future redemption windows tied to definitive agreement announcements. Because the submission is strictly procedural and limited to timing logistics and underwriter coordination, it does not modify investor exit mechanics, introduce valuation assumptions, or disclose target-level financials, customer relationships, market sizing, technology development, partnership arrangements, litigation exposures, or executive appointments. Investors monitoring the timeline should update their calendars for the targeted February 11, 2026 effectiveness, but should anticipate no substantive deal progression or covenant changes until subsequent amendment filings or proxy materials are issued.

Withdrawing an S-1 acceleration request pauses expedited SEC review of the merger prospectus, meaning the document will return to standard comment-letter processing. For investors monitoring deal progression, this extends the administrative timeline required to consummate a business combination, thereby increasing reliance on remaining uncommitted capital in trust while approaching the company’s standard two-year operating window. Attributed solely to CFO Steve Bischoff and legal contact Kevin E. Manz of King & Spalding LLP, the filing makes no substantive claims regarding customer bases, projected revenues, target market sizing, proprietary technology, strategic alliances, personnel changes, or ongoing litigation.

This S-1/A matters because it confirms the SPAC is still alive and moving toward its IPO. It provides the full terms of the proposed trust, redemptions, sponsor economics, and conflict-of-interest disclosures. Investors tracking HACQ need to note (a) the trust is expected to be $250M at $10.00/share, (b) the deadline to complete a deal is 24 months from the closing of the offering (on or about February 2028), (c) redemption rights are available for all public shareholders, regardless of how they vote, (d) the sponsor and insiders bought founder shares at ~$0.003 per share, (e) there is a mandatory $10.00 redemption if no deal is done, and (f) the sponsor team has prior SPACs with high redemption rates (83% in HCM I). The document contains no new business combination target.

This filing is the most detailed disclosure yet for HACQ's IPO, giving investors concrete terms of the offering (including trust per share of $10.00, no specified maximum redemption threshold, and a 24-month completion window extendable to 36 months), the sponsor's economic incentive (founder shares at $0.003 vs. public at $10.00), and the track record of management's prior SPAC deals (HCM I/MRNO and HCM II/IMSR). The document is material for redemption calendar tracking because it confirms the per-share trust value and the timeline for a business combination, and for sponsor conduct because it details the nominal cost of founder shares and the lock-up restrictions.

Sets terms for new SPAC: trust at $10.00 per unit, 24-month deadline from offering closing, founders' shares with 23% conversion, redemption rights, warrants at $11.50, and prior SPAC track record of management (HCM I, HCM II). No target identified yet.

What changed: A Form 8-K Current Report filing that announces the consummation of an Initial Public Offering and a simultaneous private placement, accompanied by an audited balance sheet and a going concern qualification from independent auditors. As the issuer reports, on February 13, 2026, the Company sold 28,750,000 units at $10.00 per unit, placing $287,500,000 into a U.S.-based trust account administered by Continental Stock Transfer & Trust Company. Management defines the completion window as exactly 24 months from the February 13, 2026 closing. Simultaneously, the sponsor, HCM Investor Holdings IV, LLC, and underwriter representative Cantor Fitzgerald & Co. purchased 4,666,667 private placement warrants at $1.50 per warrant, generating $7,000,000. Per the sponsor letter agreement filed with the report, the sponsor waives redemption rights for founder shares, agrees to vote all founder and post-IPO public shares in favor of a combination, and assumes liability to restore the trust account to the lesser of $10.00 per public share or actual liquidation value if third-party claims deplete it. The underwriters fully exercised their 3,750,000-unit over-allotment option, extinguishing the 1,125,000-share founder forfeiture contingency. Transaction costs totaled $19,591,443, comprising a $5,000,000 cash fee, a $13,687,500 deferred underwriting discount, and $903,943 in other costs. A $1,250,000 advisory fee was assigned to Zenith Securities LLC and reimbursed by the underwriter, with $3,062,500 remaining non-current and a separate $2,500,000 business combination advisory fee committed. On February 17, 2026, the sponsor transferred $2,474,956 to settle a $371,062 promissory note and vendor payables. Why it matters: Beyond the mechanics, the filing reveals substantial operational and strategic context that dictates near-term investor action. The independent auditor, WithumSmith+Brown, PC, issued a going concern warning, noting only $1,246,877 in working capital and a $35,000 monthly administrative services agreement with a sponsor affiliate beginning February 11, 2026, signaling pre-combination liquidity fragility dependent on continued sponsorship. Strategic disclosures confirm management has not selected any target and has initiated no substantive discussions, leaving redemption exposure purely time-driven through the February 2028 window. The founder share transfer of 75,000 units to three independent directors was valued at $114,225 ($1.52 per share) by a third-party valuation team utilizing a $9.89 implied price, 16.0% combination probability, and 9.1% volatility, which may trigger future compensation expense recognition upon a probable business combination event. Additionally, warrant valuation inputs disclose a $0.43 fair value per public warrant via a Monte Carlo model assuming 9.40% volatility and a 3.43% risk-free rate over a 2.83-year term. Because no deal progress exists, the filing’s primary materiality lies in locking the $287,500,000 trust baseline, confirming sponsor conduct commitments, and highlighting the working capital gap that could force extension votes or liquidation timelines if unaddressed.

What changed: A Form 4 insider ownership report filed February 18, 2026 (SEC file number 0001213900-26-017772) for HCM IV Acquisition Corp., submitted by director Michael J. Connor. The filing contains a single operational declaration: 'No non-derivative transactions or holdings reported.' This means the reporting director executed zero purchases, sales, conversions, or exercises of equity interests in the issuer, producing no alteration to shareholder mechanics, redemption schedules, trust accounting, extension procedures, or target-development timelines. Why it matters: According to the explicit statements in the Form 4, the document provides no new substantive developments. There are no attributed claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel changes. As a routine compliance exhibit, it confirms neutral insider positioning rather than a signal of conviction or distress, giving redemption-calendar trackers, trust-value monitors, and sponsor-conduct observers no material shift to incorporate before the stated deadline.

What changed: Form 4 insider ownership report and routine compliance exhibit. The filing records zero non-derivative transactions or holding adjustments for Shawn Matthews (Director, Chairman and CEO) and HCM Investor Holdings IV, LLC (identified as a 10% owner and Sponsor), leaving the sponsor’s equity position unchanged ahead of the documented 2028-02-12 deadline and without altering the stated $10 per-share trust valuation. Why it matters: This routine submission confirms baseline executive and sponsor alignment during the firm’s SEARCHING phase, eliminating near-term signals of management liquidity stress, early position unwinding, or pre-combination dilution. Per the filing text itself, no merger target disclosure, customer pipeline claim, revenue projection, technology roadmap, partnership agreement, litigation filing, or personnel transition is included. The document attributes the 10% sponsor stake, the $10 trust/share figure, and the 2028-02-12 expiration date exclusively to the issuer’s own records; none were calculated, rounded, or imposed from external market conventions. For investors monitoring redemption windows, trust accounting, extension voting, or sponsor conduct, the absence of insider trade activity and amendment filings indicates structural continuity rather than strategic pivot. Materiality is rated low because the exhibit introduces no new operational, financial, or corporate-action variables to the public record.

What changed: A routine compliance exhibit (SEC Form 4 insider ownership report). Director Richard Charles Donohoe’s filing explicitly states 'No non-derivative transactions or holdings reported,' confirming zero changes to his direct equity or derivative positions during the reporting window. Why it matters: This submission addresses sponsor and insider conduct by verifying no recent buying or selling activity by a company director, but provides no updates to the redemption deadline (2028-02-12), the stated trust value ($10 per share), extension timelines, or SPAC merger search progress. Beyond standard regulatory identifiers and the issuer name, the document contains no substantive claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or operational milestones. It functions solely as a periodic securities-law checkpoint rather than a developmental catalyst.

What changed: SEC Form 4 — insider ownership report identifying Director Thomas Albert Sapio as the reporting person for HCM IV Acquisition Corp. The document records zero non-derivative transactions or holdings adjustments by Director Sapio. It provides no updates on trust value per share, the 2028-02-12 redemption deadline, extension mechanics, business-combination pipeline status, or sponsor conduct. It contains no claims regarding customers, revenue, market size, strategic direction, technology, partnerships, litigation exposure, or personnel changes. Why it matters: For investors tracking redemption calendars, trust dynamics, and sponsor alignment, this filing confirms a baseline of no recent insider equity movement by the named director. The reported silence does not shift liquidation thresholds, activate extension clauses, or indicate a change in deal-sponsorship posture. It serves as a routine regulatory attestation; the lack of transactional activity preserves the existing search-phase timeline and capital structure without altering redemption-related risk parameters.

What changed: 8-K reporting the closing of HCM IV Acquisition Corp.'s initial public offering (IPO) and entry into related definitive agreements, including underwriting, warrant, trust, registration rights, private placement, and administrative support agreements. The company consummated its IPO on February 13, 2026, issuing 28,750,000 units at $10.00 per unit (including full exercise of the over-allotment option) for gross proceeds of $287,500,000, all deposited into the trust account ($10.00 per public share). Simultaneously, the sponsor and underwriter purchased 4,666,667 private placement warrants at $1.50 per warrant for $7,000,000. The company adopted amended and restated memorandum and articles of association. It also entered into a Zenith advisory agreement for IPO and business combination consulting. The company is now a public blank check company with a 24-month deadline (February 13, 2028) to complete a business combination. Why it matters: This filing establishes the fundamental trust value of $10.00 per share, the 24-month deadline, the sponsor's founder share position (8.625M shares, ~23% post-IPO), warrant terms ($11.50 strike, 5-year term, redemption at $18.00), lock-up provisions, and the start of the search period. Investors can now track trust value, redemptions, and deal progress against these baseline terms. The Zenith advisory fee structure discloses potential dilution to trust proceeds.

What changed: Final prospectus for the initial public offering of HCM IV Acquisition Corp., a blank-check SPAC selling 25 million units at $10.00 per unit, each consisting of one Class A ordinary share and one-fourth of one warrant. The SPAC has launched its IPO. No target has been selected. Trust deposits will be $250 million ($10 per unit). The completion deadline is 24 months from the IPO's closing (by February 2028). Sponsor (HCM Investor Holdings IV, LLC) holds 8.625 million founder shares purchased for $25,000. A private placement of 4,666,667 warrants at $1.50 each will raise $7 million. Non-managing sponsor investors (institutional investors) may indirectly acquire 3.5 million private warrants and 2.1 million founder shares via membership interests in the sponsor. Why it matters: This is the SPAC's foundational IPO filing. It establishes the trust value, redemption mechanics (shareholders can redeem at $10 per share plus interest, minus taxes), the 24-month deadline, sponsor economics (founder shares costing $0.003 per share vs. public $10.00), and the priority of HCM III over HACQ in deal sourcing. It also discloses that prior SPACs sponsored by the management team — HCM I (MRNO, closing price $0.94) and HCM II (IMSR, $7.41) — experienced significant post-close declines, and that 83% of HCM I shares were redeemed before its combination.

What changed: This document is a routine compliance exhibit—a Form 3 insider ownership report—stating that director Connor Michael J filed zero non-derivative transactions or holdings. Regarding redemption deadlines, trust valuation, extension votes, target development, and sponsor behavior, nothing changed. The filing documents no share acquisitions, dispositions, or derivative movements for the named director. It does not accelerate a business combination timeline, alter liquidation or redemption triggers, modify the trust account composition, announce a merger candidate, or reveal any deviation from standard SPAC governance or sponsor conduct protocols. Why it matters: For investors tracking the mechanics of capital preservation, exit windows, or acquisition pacing, this filing offers no directional signal. Because it contains no assertions about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel, and attributes no operational claims to any executive, board member, or financial advisor, it carries zero weight on redemption probability or extension risk. The reported lack of insider positioning indicates no voluntary capital commitment, leaving the SEARCHING phase and its associated calendar and trust parameters entirely dependent on subsequent merger announcements or formal extension filings rather than this administrative submission.

What changed: SEC Form 8-A for the registration of certain classes of securities pursuant to Section 12(b) of the Securities Exchange Act of 1934. The filing formally registers the registrant’s units, Class A ordinary shares (par value $0.0001 per share), and whole redeemable warrants (exercisable at $11.50 per share) for trading on The Nasdaq Stock Market LLC. It introduces no amendments to shareholder redemption windows, trust account distribution mechanics, business combination extension provisions, or target acquisition deadlines. The submission operates entirely through incorporation by reference to the security descriptions originally contained in the Company’s Registration Statement on Form S-1 (File No. 333-291343), initially filed on November 6, 2025, and adds no new tender offer structures, pro forma ownership calculations, or sponsor voting commitments. Why it matters: For investors tracking the HACQ redemption calendar and stated deadline of February 12, 2028, this filing functions as a routine post-offering compliance step that confirms the public equity and warrant classes are officially registered for secondary market listing, activating standard Nasdaq regulatory reporting pathways. It provides no commentary on the SPAC’s SEARCHING status, management’s target identification process, financial advisors engaged, or sponsor governance conduct. Because the document contains zero assertions regarding customers, revenue, market size, strategic positioning, proprietary technology, third-party partnerships, pending litigation, or executive transitions beyond the administrative signature of Chief Financial Officer Steven Bischoff dated February 11, 2026, it bears no direct impact on unit liquidation preferences or capital deployment trajectories. Investors requiring visibility into trust preservation, deal progression, or potential extension mechanisms must monitor subsequent periodic reports and definitive merger documentation rather than rely on this listing registration.